Single gene-editing dose slashes bad cholesterol by 62%

🔑 Enhanced Key Takeaways

•The gene-editing drug, VERVE-102, is an investigational in vivo base-editing medicine developed by Eli Lilly, which acquired Verve Therapeutics in June 2025 for $1.3 billion.
•VERVE-102 specifically targets and deactivates the PCSK9 gene in the liver by introducing a single DNA base pair change, leading to a reduction in PCSK9 protein levels (51% to 88%) and subsequently lowering LDL cholesterol.
•The 62% LDL cholesterol reduction was observed at the highest dose (1.0 mg/kg) in patients with heterozygous familial hypercholesterolemia (HeFH) or premature coronary artery disease (CAD), and these effects were sustained for up to 18 months in some participants.
•The therapy is delivered as a single intravenous infusion using a lipid nanoparticle (LNP) containing messenger RNA (mRNA) encoding an adenine base editor and a guide RNA (gRNA) targeting the PCSK9 gene.
•VERVE-102 is a second-generation therapy, developed after an earlier candidate, VERVE-101, faced safety concerns (liver enzyme elevations and thrombocytopenia) in its Heart-1 trial, prompting a switch to a different LNP delivery system for VERVE-102.

📊 Competitor Analysis▸ Show

Feature/Aspect	VERVE-102 (Eli Lilly/Verve Therapeutics)
Technology	Base editing (adenine base editor)
Target Gene	PCSK9
Mechanism	Permanently inactivates PCSK9 gene in liver
Delivery	Lipid Nanoparticle (LNP) with GalNAc targeting ligand
Trial Phase	Phase 1b (Heart-2 trial)
Key Results	Up to 62% LDL reduction, 51-88% PCSK9 reduction; durable up to 18 months; generally well tolerated with no treatment-related serious adverse events
Status	Moving into Phase 2 development by end of 2026
Competitor	CTX310 (CRISPR Therapeutics)
Technology	CRISPR-Cas9 gene editing
Target Gene	ANGPTL3
Mechanism	Switches off ANGPTL3 gene in liver
Delivery	Lipid Nanoparticle (LNP)
Trial Phase	Phase 1
Key Results	Up to ~50% LDL reduction and ~55% triglyceride reduction (up to 81% LDL and 81.9% triglycerides in one patient); sustained for at least 60 days (up to 90 days in one patient); well tolerated
Status	Ongoing dose escalation

🛠️ Technical Deep Dive

Mechanism of Action: VERVE-102 is an in vivo base editor designed to permanently inactivate the PCSK9 gene in the liver. It introduces a single A•T to G•C DNA change in a splice donor site of the PCSK9 gene, mimicking naturally occurring loss-of-function variants. This deactivation reduces the production of the PCSK9 protein, which normally degrades LDL receptors, thus allowing the liver to clear more LDL cholesterol from the blood.
Components: The therapy consists of a messenger RNA (mRNA) encoding an adenine base editor (ABE) protein and a specific guide RNA (gRNA) targeting the PCSK9 locus.
Delivery System: These nucleic acid components are encapsulated within a lipid nanoparticle (LNP) delivery matrix. This LNP includes an N-acetylgalactosamine (GalNAc) targeting ligand that mediates hepatocyte uptake via the asialoglycoprotein receptor, supplementing native apolipoprotein E-mediated internalization pathways. This specific LNP system for VERVE-102 (GalNAc-LNP) is a refinement over the one used for VERVE-101, which had some safety concerns.
Administration: Administered as a single intravenous infusion over approximately four hours.
Target Population: The Heart-2 trial is evaluating VERVE-102 in adults with heterozygous familial hypercholesterolemia (HeFH) or premature coronary artery disease (CAD).

🔮 Future ImplicationsAI analysis grounded in cited sources

Gene-editing therapies like VERVE-102 could transform cardiovascular care from chronic management to a one-time treatment.

The sustained LDL reduction observed for up to 18 months after a single dose suggests a durable effect, potentially eliminating the need for lifelong daily medications.

This technology could be expanded to treat a broader range of common chronic diseases beyond severe hypercholesterolemia.

The success in targeting a well-understood genetic pathway for a prevalent condition like high cholesterol opens the door for similar gene-editing approaches for other cardiometabolic or genetic diseases.

The development of base editing with improved delivery systems will enhance the safety profile of gene-editing therapies.

VERVE-102's use of a refined LNP delivery system, addressing safety concerns seen with its predecessor VERVE-101, indicates continuous improvement in minimizing adverse events associated with gene editing.

⏳ Timeline

2022-10

Preclinical studies of VERVE-101 in nonhuman primates showed durable reductions in PCSK9 and LDL-C, supporting the initiation of a first-in-human trial.

2023-11

Verve Therapeutics presented interim data from the Heart-1 trial (VERVE-101), showing dose-dependent reductions in PCSK9 and LDL-C in HeFH patients.

2024-03

VERVE-101 was deprioritized in favor of VERVE-102 due to grade 3 adverse events (liver enzyme elevations and thrombocytopenia) in the Heart-1 trial.

2025-06

Eli Lilly acquired Verve Therapeutics for $1.3 billion, integrating its gene-editing programs, including VERVE-102.

2025-11

CRISPR Therapeutics and Cleveland Clinic presented Phase 1 results for CTX310, a CRISPR-Cas9 therapy targeting ANGPTL3, showing significant reductions in LDL cholesterol and triglycerides.

2026-05

Eli Lilly announced positive Phase 1b Heart-2 study results for VERVE-102, showing up to 62% LDL-C reduction, with data presented at the European Atherosclerosis Society Congress and published in The New England Journal of Medicine.

Single gene-editing dose slashes bad cholesterol by 62%

⚡ 30-Second TL;DR

Key Points

🧠 Deep Insight

🔑 Enhanced Key Takeaways

🛠️ Technical Deep Dive

🔮 Future ImplicationsAI analysis grounded in cited sources

⏳ Timeline

📎 Sources (20)

👉Related Updates